For the psychiatry portfolio alone, Vanda is targeting annual revenue in excess of $750M in 2030, assuming the potential approval of Bysanti for the treatments of acute bipolar I disorder and schizophrenia in early 2026, the potential approval of Bysanti for the treatment of MDD, and the potential approval of Fanapt LAI.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VNDA:
- Vanda Pharmaceuticals reports Q EPS (8c) vs. (4c) last year
- Vanda’s Strategic In-Licensing of Imsidolimab Signals Promising Growth in GPP Market
- AnaptysBio, Vanda announce exclusive global license agreement for Vanda
- Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
- Vanda Pharmaceuticals (VNDA) Q4 Earnings Cheat Sheet
Questions or Comments about the article? Write to editor@tipranks.com